These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

961 related articles for article (PubMed ID: 36877356)

  • 1. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.
    Beishenaliev A; Loke YL; Goh SJ; Geo HN; Mugila M; Misran M; Chung LY; Kiew LV; Roffler S; Teo YY
    J Control Release; 2023 Jul; 359():268-286. PubMed ID: 37244297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody drug conjugates: Making 1+1>2.
    Gu Y; Wang Z; Wang Y
    Acta Pharm Sin B; 2024 May; 14(5):1965-1986. PubMed ID: 38799638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
    Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
    Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
    Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
    Zhang T; Lin Y; Gao Q
    Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
    Dabkowska A; Domka K; Firczuk M
    Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
    Jiang M; Li Q; Xu B
    Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.
    Sellmann C; Doerner A; Knuehl C; Rasche N; Sood V; Krah S; Rhiel L; Messemer A; Wesolowski J; Schuette M; Becker S; Toleikis L; Kolmar H; Hock B
    J Biol Chem; 2016 Nov; 291(48):25106-25119. PubMed ID: 27694443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of precision antibody conjugates using proximity-induced chemistry.
    Cao YJ; Yu C; Wu KL; Wang X; Liu D; Tian Z; Zhao L; Qi X; Loredo A; Chung A; Xiao H
    Theranostics; 2021; 11(18):9107-9117. PubMed ID: 34522229
    [No Abstract]   [Full Text] [Related]  

  • 20. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
    Schwach J; Abdellatif M; Stengl A
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.